Table 1 Clinical data of the studied groups
From: Epigenetic effects toward new insights as potential therapeutic target in B-thalassemia
Groups | Patients (n = 40) | Controls (n = 20) | P value |
|---|---|---|---|
Variables | |||
Sex | |||
Male (n-%) | 20–50% | 14–70% | 0.26 |
Female (n-%) | 20–50% | 6–30% |  |
Age (years) | |||
Range | 0.5–16 | 6–12 | 0.06 |
Mean ± SD | 5.16 ± 4.7 | 8.4 ± 2.12 | |
Age of onset (month) | |||
Range | 3-36 | – |  |
Mean ± SD | 12.87 ± 10.7 |  |  |
Interval of transfusion (weeks) | |||
Range | 3–8 | – |  |
Mean ± SD | 5.1 ± 2.02 |  |  |
Hemoglobin (g/dL) | |||
Mean ± SD | 7.2 ± 1.3 | 12.18 ± 1.0 | < 0.0001*** |
Hematocrit (%) | |||
Mean ± SD | 21.4 ± 4.0 | 38.9 ± 2.6 | < 0.0001*** |
RBCs count (×106/μL) | |||
Mean ± SD | 3.0 ± 0.44 | 4.66 ± 0.49 | < 0.0001*** |
MCV (fL) | |||
Mean ± SD | 65.6 ± 12.5 | 87.29 ± 5.23 | < 0.0001*** |
MCH (pg) | |||
Mean ± SD | 20.8 ± 5.2 | 29.2 ± 2.37 | < 0.0001*** |
RDW (%) | |||
Mean ± SD | 28.0 ± 8.3 | 13.3 ± 1.58 | 0.002** |
PLT (×106/μL) | |||
Mean ± SD | 426 ± 36.8 | 308 ± 54 | 0.004** |
TLC (×103/μL) | |||
Mean ± SD | 16.1 ± 1.9 | 6.1 ± 1.7 | 0.001** |
Reticulocytes count (%) | |||
Mean ± SD | 4.8 ± 1.28 | 1.4 ± 0.39 | 0.02* |
Serum Ferritin (ng/ml) | |||
Mean ± SD | 1161.8 ± 245 | 143.4 ± 24.49 | 0.003** |
Hemoglobin electrophoresis | |||
HbA (%): Mean ± SD | 42.5 ± 30.6 | 97.55 ± 0.5 | < 0.0001*** |
HbF (%): Mean ± SD | 53.5 ± 33.5 | 0.58 ± 0.18 | < 0.0001*** |
HbA2 (%): Mean ± SD | 2.8 ± 1.4 | 1.76 ± 0.56 | 0.001** |